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The current literature suggests that multiple variables aﬀect vesicoureteric reﬂux (VUR) resolution rates following dextra-
nomer/hyaluronic acid copolymer (Dx/HA) injection. This article reviews the evidence pertaining to the eﬀect of injected Dx/HA
volume on success rates following endoscopic correction. Lack of prospective studies which use injected volume as a continuous
variable coupled with a nonstandardized injection technique and endpoint hinders the ability to reach a deﬁnite conclusion.
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1. INTRODUCTION
The approval of dextranomer hyaluronic acid copolymer
(Dx/HA)bytheFDAin2001,coupledwithitssafetyandease
of injection, has led to a rapid increase in its use for treating
vesicoureteral reﬂux (VUR) [1]. This has been accompanied
by a reevaluation of the treatment philosophy for VUR,
promulgated by both a change in physician preference and
driven by parents who are opting for endoscopic correction
over long-term follow up and antibiotic prophylaxis [2,
3]. However, in the era where basic concepts about VUR
and its role in UTI and renal scarring continue to evolve,
the mere availability of a minimally invasive approach
cannot, in of itself, immediately justify the adoption of
changed indications for VUR correction. Moreover, despite
the high success rates shown in some large series, endoscopic
VUR correction using Dx/HA has not yet achieved the
success rates following open surgery [4]. It is, therefore,
imperative that factors associated with success following
Dx/HA injection are identiﬁed in order to improve surgical
outcomes, gain insight into potential mechanisms which
underlie success as well as failure, and enable better patient
selection and preoperative counseling (Table 1).
The current paper reviews the impact of injected Dx/HA
volume on primary VUR correction rates. Studies analyzing
this variable are discussed along with the ﬁndings of a recent
multivariable analysis conducted at our institution.
2. EFFECT OF INJECTION TECHNIQUE ON
THE VOLUME OF Dx/HA
The known principles for VUR correction are derived from
dissections dating back to the description of the physiologic
submucosal tunnel by Paquin in 1950s, which deﬁned the
mechanistic basis of open surgical procedures to correct
VUR [5]. By extrapolation, the goal of endoscopic injection
is to create an eﬀective valvular surrogate by providing
submucosalsupportfortheentirelengthofwhateverportion
of the reﬂuxing ureter, that is, transvesical. This is achieved
by accurate injection of suﬃcient amount of the bulking
agent in a correct plane. The hydrodistension implantation
technique (HIT) popularized by Kirsch and subsequently
modiﬁed to a double HIT procedure has highlighted the
importance of hydrodistension in enabling an intraureteric
injection to target support to the entire intravesical ureter
[6]. This technique was based on the initial description
by Chertin et al. for injection therapy in children with
high-grade VUR [7]. As opposed to the classical STING
(subtrigonal injection) technique, which aims at achieving
a good mound at the ureteral oriﬁce, the HIT tends to2 Advances in Urology
involve higher volumes of injection as it aims to support the
entire ureteric length. Moreover, obliteration of any further
hydrodistension of the ureteral oriﬁce is the endpoint in this
technique rather than a good mound. Clearly, establishing
this endpoint may further lead to higher injection volumes.
Therefore,reportedvolumesofinjectioninallstudiesshould
be interpreted with caution, and both technique and volume
should be studied as distinct variables in a multivariable
analysis.
3. EFFECT OF INJECTED Dx/HA VOLUME
ON OUTCOME
The mean injected volume of Dx/HA injected in all series
reported to date varies between 0.2mL to >1mL[2, 3, 6, 8–
16]. The impact of injected volume on success is variable
(Table 2). Kirsch et al. found no statistical diﬀerence in
injected volume between successes and failures using a mean
of 0.83mL in 459 ureters [8]. In a follow up study using a
mean volume of 0.9mL, the same authors demonstrated a
positive impact of increasing experience as well as injected
volume,withimprovedsuccessratesfrom60to74%[6].The
third variable, which then prompted a further improvement
in the success rate to 89%, was the use of the “modiﬁed
STING” or HIT. The HIT technique involves placing the
needle into the mid to distal ureteral tunnel itself at the 6-
o’ clock position and watching the entire tunnel coapt as
the injection progresses. In contrast, the traditional STING
technique, judged by both the mechanism and endpoint
of injection (a mound at the ureteral oriﬁce alone, not
involving the intravesical ureter, and in eﬀect creating a
surrogate nipple valve rather than ﬂap valve mechanism
at the ureteral oriﬁce to prevent VUR) would presumably
require a relatively lesser injected volume. Though not
highlighted in the paper, the injected volumes were indeed
higher in this subset of patients (1–1.5mL), compared to the
STING group.
In contrast, in two subsequent studies where mean
injected volumes of Dx/HA were ≥0.8mL, no correlation
with VUR correction was noted [9, 10]. Lavelle et al.
reported that the average injected volume was 0.84mL in
those with successful VUR correction when compared with
0.94mL in failures (p = NS) [9]. Mound morphology
was the only statistically signiﬁcant predictor of success;
87% of ureters that showed a “volcano” conﬁguration were
correctedasopposedtoonly53%inthosewithan“alternate”
morphology. Although Routh et al. did not demonstrate
an eﬀect of injected volume in their study, the authors
acknowledged that their injection volume had increased over
time based on the positive experience of other authors [10].
Yucel et al. performed a multivariable analysis of their
experience with Dx/HA injection and showed that an
injected volume of <0.5mL was signiﬁcantly associated with
success as compared to a volume >0.5mL [11]. The overall
reﬂux correction was 70% by patients and 78% by ureters
(mean VUR grade 2.6) as compared to 89% and 92%,
respectively (mean VUR grade 2.6), in the study by Kirsch
et al. [6]. Similar to the ﬁndings of Lavelle et al., this study
showed that mound morphology was the most important
indicator of VUR correction. The authors speculated that a
higher volume of Dx/HA implied a technically more diﬃcult
injection resulting in a poorer outcome. No evidence was
provided to support this conjecture. Moreover, it is unlikely
that all injections in the HIT series by Kirsch et al. were
uniformlymorediﬃculttoaloneaccountforgreaterinjected
volumes. As stated above, a priori performance of a double
HIT injection is likely to require more injected material.
Alternatively, the ﬁndings of Yucel et al. may reﬂect that
the analysis was based on a cutoﬀ close to their mean
injected volume, rather than treating the injected volume as
ac o n t i n u o u sv a r i a b l e .
Another multivariable analysis published in 2007
attempted to look at the eﬀect of volume using a 1mL cutoﬀ.
Routh et al. treated 301 patients (453 ureters) with VUR
using an average 0.93mL Dx/HA with a 75.5% success rate
by ureters [12]. The authors noted that preoperative VUR
grade and the operating surgeon were signiﬁcant predictors
of outcome. The technique of injection (HIT versus STING)
was signiﬁcant on a univariate analysis but only showed a
trend toward signiﬁcance for HIT on a multivariable analysis
(P = .056). However, with respect to volume, no diﬀerence
in success rates was noted when injected Dx/HA volume was
analyzed as a cutoﬀ of <1mLor>1mL. It is possible that
arbitrarily choosing a 1mL cutoﬀ volume may have missed
an actual signiﬁcant cutoﬀ volume, thereby, failing to detect
any volume eﬀect. Moreover, as rightly pointed out by the
authors, there is also a possibility that the positive eﬀect of
higher volume is nulliﬁed by the fact that higher volumes are
more likely to be used for higher grades of VUR.
We performed a retrospective review of 126 consecutive
patients with primary VUR (196 reﬂuxing ureters) who
underwentinjectionforfebrileurinarytractinfections(UTI)
to identify factors associated with success following Dx/HA
injection [13]. Endoscopic injection was performed using
both the STING and the HIT techniques in this series
thoughneitherwereprospectivelyplannedinanypatientnor
systematically varied over the course of the series. Success
wasdeﬁnedasresolutionofVURafterﬁrstinjectiononpost-
operative VCUG performed 3 months following endoscopic
treatment. Univariate and multivariate regression analysis
were performed on the following variables: age at surgery,
gender, laterality, time between presentation and surgery,
preoperative VUR grade, surgeon experience, lower urinary
tract symptoms (LUTS), and volume of Dx/HA injection.
Statistical analysis was performed with SPSS version 13.0
software (SPSS Inc., Chicago, Ill, USA), with P-values less
than .05 considered statistically signiﬁcant.
By renal unit, VUR grades were as follows: I in 7(3.5%),
II in 53(27%), III in 91(46.4%), IV in 30(15.3%), and V
in 15(7.6%), with a mean VUR grade of 3. Success rate
after 1 injection was 50% by patient and 59.2% by ureter.
Success rate by grade was 100% for grade I, 75% for grade
II, 57% for grade III, 37% for grade IV, and 46% for grade
V. Mean injected volume was 0.9 ± 0.27mL in those who
had a successful injection versus 0.67 ± 0.24mL in those
who failed (P<. 001). Success after 1 injection was 78.9%
using ≥0.8mL Dx/HA compared to 31.7% with <0.8mL.
The mean Dx/HA volume increased from 0.75 ± 0.26mL inS .D a v ea n dD .J .B¨ agli 3
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Figure 1: VUR correction rates for each 0.1mL increment in
injected Dx/HA volume.
the ﬁrst 98 ureters treated to 0.87 ± 0.29mL in the last 98
(P = .002), a change that was associated with a simultaneous
improvement in the success rate for grade III VUR from 50
to 68%. This increase in injected volume was not prompted
by an interim assessment of our results, though it can
be speculated that it may be a reﬂection of a change in
technique form the classical STING to the HIT (see above).
However, there was no statistical diﬀerence in the mean
injected volume for high- and low-grade VUR: I–II (0.82 ±
0.29mL)versusIII–IV(0.78±0.26mL),indicatingthatgrade
did not inﬂuence injection volume across the series. The
success rates for each 0.1mL increase in injected Dx/HA
volume is plotted in Figure 1. Our analysis showed that
for each 0.1mL increment in the injected Dx/HA volume,
a statistically signiﬁcant improvement in success rate was
observed when compared to correction achieved below that
cutoﬀvolume.Thisvolumeeﬀectpersisteduptoamaximum
of 1mL injected beyond which no further increase in success
ratewasobserved(seediscussionofarbitrarychoiceofcutoﬀ
volume in [12] above). Multivariable analysis conﬁrmed that
higher Dx/HA volume (P = .001), lower preoperative grade
(P = .013), surgeon experience (P = .025), and treatment
of LUTS (P = .009) were all independently associated with
successful correction of VUR.
4. CAN INJECTED VOLUME IN ASSOCIATION WITH
OBLITERATION OF HYDRODISTENSION BE USED IN
COMBINATION TO PREDICT SUCCESS?
The use of mound morphology as the injection progresses as
a predictor of VUR resolution is fraught with some inherent
drawbacks. What deﬁnes a “good” mound is a subjective
measure much like the subjectivity of the “good urethral
plate” in hypospadias surgery; both are qualitative, diﬃcult
to deﬁne, and are based on surgeon experience. Secondly,
the mound is a 2-dimensional view of the eﬀect of the
injection at the ureteric oriﬁce, but gives no indication of the
Table 1: Reported variables associated with VUR correction using
Dx/HA.
Variables associated with VUR correction following Dx/HA
injection
(1) Mound morphology
(2) Grade of VUR
(3) Surgeon experience/learning curve
(4) Injection technique
(5) Volume of Dx/HA
(6) Absence of ureteric dilatation
(7) Location of ureteral oriﬁce (degree of lateral ectopia)
(8) Age of patient
(9) Resident participation
(10) Fewer needle insertions
(11) Absence or correction of lower urinary tract symptoms
support achieved, if any, along the entire intra vesical ureter.
In addition, the mound at injection may not be the mound
at the time of reassessment by a VCUG at 3 months. There
is a well-documented 19% decrease in the injected Dx/HA
bolus over 3 months [8]. This volume reduction occurs
because the dextranomer microspheres constitute 50% of
the volume in Dx/HA and their hydrolysis overtime will
alter the mound morphology, likely shrinking it somewhat,
notwithstanding the stabilizing eﬀect of collagen ingrowth
[17]. This coupled with a risk of bolus migration would
mean that the surgeon could use mound morphology as
a predictor of VUR correction at the time of injection but
this endpoint may not be a stable indicator of longer term
success. In studies which showed the eﬀect of a “favorable”
mound morphology on outcome, VUR resolved in 53% of
ureters in Lavelle’s series and in 36% in the study by Yucel
et al. [11]. Moreover, up to 12% of “good” mounds can have
persistent VUR following Dx/HA injection [18].
These studies all share the inherent limitations of
nonrandomized retrospective reviews. In the present paper,
this primarily involves failure to identify and include of
all confounding variables which could impact the results.
For example, one of the criticisms of our study is that the
techniqueofinjection(HITversusSTING)wasnotanalyzed.
Moreover, the very indications for treatment of the reﬂux
vary from study to study, along with the severity of VUR
further confounding the results and their comparison with
other studies.
5. CONCLUSIONS
There are several factors which may predict successful VUR
correction following Dx/HA injection. Our study revealed
the presence of a direct association between injected volume
and VUR correction, by treating volume as a continu-
ous variable, even while controlling for other variables,
highlighting its importance as a true success modiﬁer.
The injected volume of Dx/HA is a factor, which to a
degree under the direct control of the surgeon. Given the
exigencies of materials cost, and the expectation on surgeons4 Advances in Urology
Table 2: Studies investigating the eﬀect of injected Dx/HA volume on VUR correction.
Series Reﬂuxing units; mean Mean Volume injected (mL) Method of statistical Success by Eﬀect of volume of
Dx/HA volume (mL) grade success/failures analysis grade (%) injected Dx/HA
Kirsch 2003 292 2.6 S: 0.9 ±0.3 Univariate I 90; II 82; NS
0.83 ±0.03 F: 0.9 ±0.2 III 73; IV 65
Kirsch 2004 119 S: 1.0 I 100; II 90; Higher
modiﬁed >0.9 2.8 F: 1.5 Univariate III 91; IV 89 volume
STING signiﬁcant
Lavelle 80 NA S: 0.8 Univariate I 82; II 84; NS
2005 NA F: 0.9 III 77; IV 73
Routh 225 pts 2.4 S: 0.8 (0.4–2.0) Univariate I 63; II 72; III 57; NS
2006 0.8 (0.3–2.0) F: 0.8 (0.3–1.8) IV 14 (By patients)
2.6 NA
Studied as categorical I 100; II 83; Lower (<0.5)
Yucel 259 variable with cutoﬀ III 73; volume
2007 0.54 ±0.2 </>0.5mL using IV 53, signiﬁcant
multivariable analysis V 29
2.3 NA
Studied as categorical I 83;
NS Routh 453 variable with cut oﬀ II 82;
2007 0.93 (0.2–3.5) </>1mL using III 66;
multivariable analysis IV 53
3
I 100, Higher
Dave 2007 196 S: 0.9 ±0.2 Studied as continuous II 75; volume
(Accepted J 0.8 ±0.03 F: 0.6 ±0.2 variable using III 57; signiﬁcant on
Urol) multivariable analysis IV 37; multivariable
V 46 analysis
to use available medical resources responsibly, without a
clear demonstration of the eﬀect of volume on results,
t h es u r g e o ni st oac e r t a i ne x t e n th e s i t a n tt ou s eo n l ya
small portion of a second Dx/HA syringe, beyond the 0.8–
1mL available for injection in the standard commercially
available syringe. Based on our experience, we now adopt a
more aggressive approach in injecting a minimum of 0.8mL
irrespective of the grade of VUR and ensure obliteration of
hydrodistension at the end of injection. From a cost stand
point, an injection failure deﬁnitely involves higher costs
and, therefore, it is reasonable to use a higher volume at the
initialattempttoimprovesuccessrates.Syringeswithslightly
greater volumes of 1.2–1.4mL, should they become available
in the future, may provide greater treatment ﬂexibility in
this regard. Finally, though endoscopic injection for VUR
is generally accepted as a simple procedure, the importance
of technique and experience are evident in most studies.
Further prospective studies which include all variables, and
which possibly perform hydrodistension in a standardized
manner, need to be conducted to identify factors which can
be used for patient counselling, and increase success rates to
those won by open correction of VUR.
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